Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038

NCT05429294 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

209

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: Pyrotinib

Sponsor

First Affiliated Hospital Xi'an Jiaotong University